- NeuroSearch division, NsDiscovery, extends the alliance period with Janssen to August 2013
- Total fixed payments from Janssen are unchanged
NeuroSearch (NEUR) today announces an agreement with Janssen Pharmaceutica NV to extend the ongoing collaboration until August 2013. The extension will not impact on the total number of NeuroSearch scientists working within the alliance, and the financial terms (total fixed payments, as well as milestones and royalties) remain unchanged.
NeuroSearch entered into the alliance with Janssen in August 2009 building on joint expertises in neuroscience drug discovery and development.
Thomas Varming, EVP and Director of NsDiscovery:
"Our collaboration with Janssen progresses very satisfactory, and we are pleased that our relationship will continue at least for one extra year."
Patrik Dahlen
CEO
Contact persons:
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil® through an in-house marketing and sales organisation.
NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and CNS diseases. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of unlisted companies in the Life Science industry.
